Executive summary of the 2020 Clinical practice guidelines for the management of Dyslipidemia in the Philippines
https://doi.org/10.15605/jafes.036.01.01
- Author:
Lourdes Ella Gonzalez-Santos
1
;
Raymond Oliva
1
;
Cecilia Jimeno
2
;
Eddieson Gonzales
3
;
Maria Margarita Balabagno
4
;
Deborah Ona
1
;
Jude Erric Cinco
5
;
Agnes Baston
6
;
Imelda Caole-Ang
7
;
Mia Fojas
8
;
Ruzenette Felicitas Hernandez
9
;
Ma. Cristina Macrohon-Valdez
10
;
Maria Theresa Rosqueta
11
;
Felix Eduardo Punzalan
12
;
Elmer Jasper Llanes
12
Author Information
1. Division of Hypertension, Department of Medicine, University of the Philippines College of Medicine-Philippine General Hospital
2. Department of Pharmacology and Toxicology, University of the Philippines College of Medicine
3. Department of Internal Medicine, Batangas Medical Center, Philippines
4. Department of Cardiology, Perpetual Help DALTA Medical Center-Las Pinas City, Philippines
5. Department of Cardiology, The Medical City, Pasig City, Philippines
6. Department of Internal Medicine, Emilio Aguinaldo College Medical Center-Cavite, Philippines
7. College of Medicine, Pamantasan ng Lungsod ng Maynila, Philippines
8. Department of Biochemistry and Molecular Biology, University of the Philippines College of Medicine
9. Department of Pediatrics, De La Salle University Medical Center and De La Salle Health Science Institute, College of Medicine, Dasmarinas, Cavite, Philippines
10. Institute of Neurosciences, St. Lukes Medical Center, Global City, Taguig, Philippines
11. Philippine Heart Center
12. Division of Cardiovascular Medicine, Department of Medicine, University of the Philippines College of Medicine-Philippine General Hospital
- Publication Type:Journal Article
- Keywords:
Guidelines;
Cardiovascular prevention
- MeSH:
Dyslipidemias;
Hyperlipoproteinemia Type II;
Diabetes Mellitus
- From:
Journal of the ASEAN Federation of Endocrine Societies
2021;36(1):5-11
- CountryPhilippines
- Language:English
-
Abstract:
Dyslipidemia is a cardiovascular risk factor that is increasing in prevalence in the country. The need to treat and manage elevated cholesterol levels, both pharmacologic and non-pharmacologic, is of utmost importance. Different medical societies and groups bonded together to formulate the 2020 Philippine Clinical Practice Guidelines for dyslipidemia. The group raised nine clinical questions that are important in dyslipidemia management. A technical working group analyzed the clinical questions dealing with non-pharmacologic management, primary prevention for both non-diabetic and individuals with diabetes, familial hypercholesterolemia, secondary prevention, adverse events of statins and the use of other lipid parameters as measurement of risk for cardiovascular disease. Randomized controlled trials and meta-analyses were included in the GRADE-PRO analysis to come up with the statements answering the clinical questions. The statements were presented to a panel consisting of government agencies, members of the different medical societies, and private institutions, and the statements were voted upon to come up with the final statements of the 2020 practice guidelines. The 2020 CPG is aimed for the Filipino physician to confidently care for the individual with dyslipidemia and eventually lower his risk for cardiovascular disease.
- Full text:927-Article Text-12687-4-10-20210601.pdf
